Zobrazeno 1 - 10
of 163
pro vyhledávání: '"Maerevoet M"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Background: Despite a number of treatment options, patients with diffuse large B-cell lymphoma (DLBCL) whose disease has become refractory to treatment have a poor prognosis. Selinexor is a novel, oral drug that is approved to treat patients with rel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::c68321e34dc803adc3440696e2f723b6
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076911
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3076911
Autor:
Shah, J., Shacham, S., Kauffman, M., Daniele, P., Tomaras, D., Tremblay, G., Casasnovas, R.O., Maerevoet, M., Zijlstra, J., Follows, G., Vermaat, J.S.P., Kalakonda, N., Goy, A.H., Choquet, S., Neste, E. van den, Hill, B.T., Thieblemont, C., Cavallo, F., Cruz, F. de la, Kuruvilla, J., Hamad, N., Bouabdallah, R., Jager, U., Caimi, P., Gurion, R., Warzocha, K., Bakhshi, S., Sancho, J.M., Schuster, M., Egyed, M., Offner, F., Vasilakopoulos, T.P., Samal, P., Nagy, A., Ku, M., Albendea, M.A.C.
Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10693::17cd4bbfd2cf83de9a819f46f1821002
https://hdl.handle.net/1887/3279611
https://hdl.handle.net/1887/3279611
Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::0e2f811591694d3135f36e92cda83222
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077132
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077132
Autor:
Shah, J, Shacham, S, Kauffman, M, Daniele, P, Tomaras, D, Tremblay, G, Casasnovas, RO, Maerevoet, M, Zijlstra, J, Follows, G, Vermaat, JSP, Kalakonda, N, Goy, AH, Choquet, S, Van den Neste, E, Hill, BT, Thieblemont, C, Cavallo, F, de la Cruz, F, Kuruvilla, J, Hamad, N, Bouabdallah, R, Jager, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, JM, Schuster, M, Egyed, M, Offner, F, Vasilakopoulos, TP, Samal, P, Nagy, A, Ku, M, Albendea, MAC
Publikováno v:
Future Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::bab2c32ec5c9f18330933aa07d83fa62
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4021
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4021
Autor:
Morschhauser, Franck, Fowler, Nathan H, Feugier, Pierre, Bouabdallah, Reda, Tilly, Hervé, Palomba, M Lia, Fruchart, Christophe, Libby, Edward N, Casasnovas, Rene-Olivier, Flinn, Ian W, Haioun, Corinne, Maisonneuve, Hervé, Ysebaert, Loic, Bartlett, Nancy L, Bouabdallah, Kamal, Brice, Pauline, Ribrag, Vincent, Daguindau, Nicolas, Le Gouill, Steven, Pica, Gian M, Martin Garcia-Sancho, Alejandro, López-Guillermo, Armando, Larouche, Jean-François, Ando, Kiyoshi, Gomes da Silva, Maria, André, Marc, Zachée, Pierre, Sehn, Laurie H, Tobinai, Kensei, Cartron, Guillaume, Liu, David, Wang, Jianming, Xerri, Luc, Salles, Gilles A, Abdel-Samad N, Abdo-Matkiwsky M, Abraham J, Abrisqueta P, Anglaret B, Barnes JA, Benbrahim O, Bierman PJ, Bonnet C, Brault P, Bron D, Brooks BJ Jr, Byeff P, Casanova M, Cheung M, Choudhary Y, Comeau T, Cooper B, Couban S, Cox MC, Crump M, Deau Fischer B, Deconinck E, Deeren D, de la Cruz Vicente F, Delarue R, Del Campo R, Delmer A, Delwail V, Duggan PR, Eisenmann DJRM, El Yamani A, Eradat HA, Fabbro M, Farber C, Fisher DC, Fleischman RA, Fleck E, Fornecker LM, Foussard C, Gabarre J, Gaffar YA, Gallardo D, Ghazal H, Giagounidis A, Gill K, Glaisner S, Gonzalez H, Greenberg RH, Goubran Messiha H, Goy A, Gressin R, Gyan E, Hart LL, Hatake K, Hiddemann W, Hodossy B, Horkheimer I, Hoyer RJ, Huebel K, Ishikawa T, Izutsu K, Jardel H, Jhangiani HS, Johnson N, Joly B, Jourdan E, Kargar Samani K, Kato K, Kiguchi T, Kobayashi T, Kohser F, Koike M, Kouroukis C T, Laferriere N, Lamy de la Chapelle T, Landau DA, Lawler WE, Lemieux B, Levitan DA, Longree L, Lopez J, Mace J, Maerevoet M, Maigre M, Marjanovic Z, Michel J, Mounier C, Muntanola A, Ngirabacu MC, Nicolas-Virelizier E, Novelli S, Offner F, Palomera L, Pandit LH, Panwalkar A, Pierre P, Pignon JM, Pinto A, Plöger C, Pranger D, Quick DP, Reyes EA, Robin V, Robu D, Rodriguez Salazar MJ, Rosen PJ, Rosenbluth J, Sadot-Lebouvier S, Sangha R, Segota Z, Shapira I, Shtivelband M, Simon M, Soekler M, Soubeyran P, Taper J, Tereblo HR, Terol MJ, The AS, Ueda Y, van den Neste E, van Eygen K, van Hoof A, Vanstraelen G, Verner E, Warburton P, Yamamoto G, Yokoyama H, Zerazhi H, Zinzani PL.
Publikováno v:
New England Journal of Medicine
New England Journal of Medicine, 2018, 379 (10), pp.934-947. ⟨10.1056/nejmoa1805104⟩
New England Journal of Medicine, Massachusetts Medical Society, 2018, 379 (10), pp.934-947. ⟨10.1056/nejmoa1805104⟩
New England Journal of Medicine, 2018, 379 (10), pp.934-947. ⟨10.1056/nejmoa1805104⟩
New England Journal of Medicine, Massachusetts Medical Society, 2018, 379 (10), pp.934-947. ⟨10.1056/nejmoa1805104⟩
International audience; BACKGROUND:Rituximab plus chemotherapy has been shown to be effective in patients with advanced-stage, previously untreated follicular lymphoma; nevertheless, most patients will have a relapse. Combination immunotherapy with l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3989a335983ccc37800421665ae98b9
http://hdl.handle.net/11585/674313
http://hdl.handle.net/11585/674313
Autor:
Kalakonda, N., Maerevoet, M., Cavallo, F., Follows, G., Goy, A., Vermaat, J.S.P., Casasnovas, O., Hamad, N., Zijlstra, J.M., Bakhshi, S., Bouabdallah, R., Choquet, S., Gurion, R., Hill, B., Jaeger, U., Sancho, J.M., Schuster, M., Thieblemont, C., Cruz, F. de la, Egyed, M., Mishra, S., Offner, F., Vassilakopoulos, T.P., Warzocha, K., McCarthy, D., Ma, X.W., Corona, K., Saint-Martin, J.R., Chang, H., Landesman, Y., Joshi, A., Wang, H.W., Shah, J., Shacham, S., Kauffman, M., Neste, E. van den, Canales, M.A.
Publikováno v:
Lancet Haematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Lancet Haematology, 7(7), E509-E522. ELSEVIER SCI LTD
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Lancet Haematology, 7(7), E509-E522. ELSEVIER SCI LTD
Background Relapsed or refractory diffuse large B -cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. We aimed to assess the response to single -agent selinexor, an oral selective inhibitor of nuclear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0b56206d52c8c303f1c0c046e72501ef
https://hdl.handle.net/1887/3185058
https://hdl.handle.net/1887/3185058
Background: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer with a median overall survival of less than 6 months. We aimed to assess the response to single-agent selinexor, an oral selective inhibitor of nuclear e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::ac17a2b3b05bdd673e3fd024addf412e
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3104269
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3104269
Autor:
Casasnovas, RO, Daniele, P, Tremblay, G, Maerevoet, M, Zijlstra, J, Follows, G, Vermaat, JSP, Kalakonda, N, Goy, AH, Choquet, S, Van den Neste, E, Hill, BT, Thieblemont, C, Cavallo, F, de la Cruz, F, Kuruvilla, J, Hamad, N, Bouabdallah, R, Jager, U, Caimi, P, Gurion, R, Warzocha, K, Bakhshi, S, Sancho, JM, Schuster, M, Egyed, M, Offner, F, Vasilakopoulos, T, Samal, P, Nagy, A, Ku, M, Albendea, MAC
Publikováno v:
Value in Health
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::3446efc5e98443c2400b04c7fdddc462
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4213
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4213
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.